Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Experimental and Therapeutic Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-0981 Online ISSN: 1792-1015
Journal Cover
October-2021 Volume 22 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
October-2021 Volume 22 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Inhibition of miR‑483‑5p improves the proliferation, invasion and inflammatory response of triple‑negative breast cancer cells by targeting SOCS3

  • Authors:
    • Jianbo Ren
    • Gang Xu
    • Hongyan Sun
    • Ting Lin
    • Sanhui Xu
    • Yating Zhao
  • View Affiliations / Copyright

    Affiliations: Department of Oncology, Yantai Muping Hospital of Traditional Chinese Medicine, Yantai, Shandong 264100, P.R. China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China, Endoscopy Center, Yantai Muping Hospital of Traditional Chinese Medicine, Yantai, Shandong 264100, P.R. China, Department of Breast Surgery, Tangshan People's Hospital, Lunan, Tangshan, Hebei 063000, P.R. China, 1st Laboratory Department, Xingtai People's Hospital, Xingtai, Hebei 054000, P.R. China, Breast Health Department, Tangshan Maternal Child Health Care Hospital, Tangshan, Hebei 063000, P.R. China
    Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Article Number: 1047
    |
    Published online on: July 22, 2021
       https://doi.org/10.3892/etm.2021.10480
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

microRNAs (miRs) have been indicated to serve oncogenic or tumor suppressor roles. However, the role of miR‑483‑5p in breast cancer and its associated molecular mechanisms remain unclear. In the present study, compared with adjacent normal tissues and MCF‑10a cells, the expression level of miR‑483‑5p was upregulated in triple‑negative breast cancer (TNBC) tissues and TNBC cell lines. Bioinformatic analysis and luciferase reporter assay confirmed the presence of miR‑483‑5p binding sites in the 3'‑untranslated region of suppressor of cytokine signaling 3 (SOCS3). In addition, the expression level of SOCS3 protein in TNBC tissues was markedly lower compared with in adjacent tissues, and miR‑483‑5p expression was negatively correlated with SOCS3 expression in TNBC tissues. Cell proliferation and flow cytometry assays indicated that knockdown of miR‑483‑5p inhibited the proliferation and promoted apoptosis in the TNBC cell line BT‑549. This effect was markedly attenuated by SOCS3 small interfering (si)RNA transfection. Additionally, wound healing and Transwell assays demonstrated that SOCS3 siRNA reversed the inhibitory effects of miR‑483‑5p inhibitor on the migration and invasion of BT‑549 cells. Moreover, the decrease in miR‑483‑5p expression significantly reduced the secretion of TNF‑α, IL‑6, IL‑1β and monocyte chemoattractant protein‑1 in BT‑549 cells, while SOCS3 siRNA could partially reverse this effect. Additionally, SOCS3 overexpression reversed the effects of miR‑483‑5p mimic on the proliferation, migration, invasion and inflammation of BT‑549 cells. Taken together, these data demonstrated that the inhibition of miR‑483‑5p could inhibit the proliferation, migration, invasion and inflammatory response, while promoting the apoptosis of TNBC cells by negatively regulating SOCS3. miR‑483‑5p may be a potential target for TNBC therapy.
View Figures

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

View References

1 

Domínguez F, Maycotte P, Acosta-Casique A, Rodríguez-Rodríguez S, Moreno DA, Ferreres F, Flores-Alonso JC, Delgado-López MG, Pérez-Santos M and Anaya-Ruiz Μ: Bursera copallifera Extracts have cytotoxic and migration-inhibitory effects in breast cancer cell lines. Integr Cancer Ther. 17:654–664. 2018.PubMed/NCBI View Article : Google Scholar

2 

Geenen JJJ, Linn SC, Beijnen JH and Schellens JH: PARP inhibitors in the treatment of triple-negative breast cancer. Clin Pharmacokinet. 57:427–437. 2018.PubMed/NCBI View Article : Google Scholar

3 

Liu J, Shi Z, Bai Y, Liu L and Cheng K: Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer. Cancer Manag Res. 11:4471–4480. 2019.PubMed/NCBI View Article : Google Scholar

4 

Paul S, Reyes PR, Garza BS and Sharma A: MicroRNAs and child neuropsychiatric disorders: A Brief Review. Neurochem Res. 45:232–40. 2020.PubMed/NCBI View Article : Google Scholar

5 

Dai W, Lu H, Yang F, Dong H and Zhang X: Accurate detection of intracellular microRNAs using functional Mo2C quantum dots nanoprobe. Chem Commun (Camb). 55:10615–10618. 2019.PubMed/NCBI View Article : Google Scholar

6 

Li H, He C, Wang X, Wang H, Nan G and Fang L: MicroRNA-183 affects the development of gastric cancer by regulating autophagy via MALAT1-miR-183-SIRT1 axis and PI3K/AKT/mTOR signals. Artif Cells Nanomed Biotechnol. 47:3163–3171. 2019.PubMed/NCBI View Article : Google Scholar

7 

Lou Q, Liu R, Yang X, Li W, Huang L, Wei L, Tan H, Xiang N, Chan K, Chen J, et al: miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer. J Immunother Cancer. 7(210)2019.PubMed/NCBI View Article : Google Scholar

8 

Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 449:682–688. 2007.PubMed/NCBI View Article : Google Scholar

9 

Sahraei M, Chaube B, Liu Y, Sun J, Kaplan A, Price NL, Ding W, Oyaghire S, García-Milian R, Mehta S, et al: Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. J Clin Invest. 129:5518–5536. 2019.PubMed/NCBI View Article : Google Scholar

10 

Li H, Bian C, Liao L, Li J and Zhao RC: miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat. 126:565–575. 2011.PubMed/NCBI View Article : Google Scholar

11 

Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 403:901–906. 2000.PubMed/NCBI View Article : Google Scholar

12 

Gao Y, Zhang W, Liu C and Li G: miR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB. Sci Rep. 9(18844)2019.PubMed/NCBI View Article : Google Scholar

13 

Girardot M, Cavaillé J and Feil R: Small regulatory RNAs controlled by genomic imprinting and their contribution to human disease. Epigenetics. 7:1341–1348. 2012.PubMed/NCBI View Article : Google Scholar

14 

Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG, et al: miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res. 15:7684–7692. 2009.PubMed/NCBI View Article : Google Scholar

15 

Song Q, Xu Y, Yang C, Chen Z, Jia C, Chen J, Zhang Y, Lai P, Fan X, Zhou X, et al: miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res. 74:3031–3042. 2014.PubMed/NCBI View Article : Google Scholar

16 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar

17 

Meirson T and Gil-Henn H: Targeting invadopodia for blocking breast cancer metastasis. Drug Resist Updat. 39:1–17. 2018.PubMed/NCBI View Article : Google Scholar

18 

De Sanctis V, Agolli L, Visco V, Monaco F, Muni R, Spagnoli A, Campanella B, Valeriani M, Minniti G, Osti MF, et al: Cytokines, fatigue, and cutaneous erythema in early stage breast cancer patients receiving adjuvant radiation therapy. Biomed Res Int. 2014(523568)2014.PubMed/NCBI View Article : Google Scholar

19 

Zhang H, Shi X, Chang W, Li Y and Wang L and Wang L: Epigenetic alterations of the Igf2 promoter and the effect of miR 483 5p on its target gene expression in esophageal squamous cell carcinoma. Mol Med Rep. 17:2251–2256. 2018.PubMed/NCBI View Article : Google Scholar

20 

Wang L, Shi M, Hou S, Ding B, Liu L, Ji X, Zhang J and Deng Y: MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1. FEBS Lett. 586:1312–1317. 2012.PubMed/NCBI View Article : Google Scholar

21 

Lemberger M, Loewenstein S, Lubezky N, Nizri E, Pasmanik-Chor M, Barazovsky E, Klausner JM and Lahat G: MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis. Oncotarget. 10:2644–2656. 2019.PubMed/NCBI View Article : Google Scholar

22 

Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, et al: MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 8(R214)2007.PubMed/NCBI View Article : Google Scholar

23 

Conteduca V, Caffo O, Galli L, Maugeri A, Scarpi E, Maines F, Chiuri VE, Cristian Lolli C, Kinspergher S, Schepisi G, et al: Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urol Oncol. 36:240.e1–.e11. 2018.PubMed/NCBI View Article : Google Scholar

24 

Garbers C and Rose-John S: Dissecting interleukin-6 classic-and trans-signaling in inflammation and cancer. Methods Mol Biol. 1725:127–140. 2018.PubMed/NCBI View Article : Google Scholar

25 

Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, Malik F, Paulson AK, D'Angelo RC, Korkaya S, et al: SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene. 34:671–680. 2015.PubMed/NCBI View Article : Google Scholar

26 

Klepsch O, Namer LS, Köhler N, Kaempfer R, Dittrich A and Schaper F: Intragenic regulation of SOCS3 isoforms. Cell Commun Signal. 17(70)2019.PubMed/NCBI View Article : Google Scholar

27 

Li H, Zhang B, Ding M, Lu S, Zhou H, Sun D, Wu G and Gan X: C1QTNF1-AS1 regulates the occurrence and development of hepatocellular carcinoma by regulating miR-221-3p/SOCS3. Hepatol Int. 13:277–292. 2019.PubMed/NCBI View Article : Google Scholar

28 

Singh S, Chouhan S, Mohammad N and Bhat MK: Resistin causes G1 arrest in colon cancer cells through upregulation of SOCS3. FEBS Lett. 591:1371–1382. 2017.PubMed/NCBI View Article : Google Scholar

29 

Li MZ, Lai DH, Zhao HB, Chen Z, Huang QX and Situ J: SOCS3 overexpression enhances ADM resistance in bladder cancer T24 cells. Eur Rev Med Pharmacol Sci. 21:3005–3011. 2017.PubMed/NCBI

30 

Muhammad N, Bhattacharya S, Steele R and Ray RB: Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. Oncotarget. 7:58595–58605. 2016.PubMed/NCBI View Article : Google Scholar

31 

Christopher AF, Gupta M and Bansal P: Micronome revealed miR-19a/b as key regulator of SOCS3 during cancer related inflammation of oral squamous cell carcinoma. Gene. 594:30–40. 2016.PubMed/NCBI View Article : Google Scholar

32 

Zakaria N, Mohd Yusoff N, Zakaria Z, Widera D and Yahaya BH: Inhibition of NF-κB signaling reduces the stemness characteristics of lung ccancer stem cells. Front Oncol. 8(166)2018.PubMed/NCBI View Article : Google Scholar

33 

Zhang X, Wan Q and Xu TS: Effect of Grain-moxibustion on IL-6 and STAT 3 in inflammatory microenvironment of Lewis lung cancer mice. Zhen Ci Yan Jiu. 42:235–239. 2017.PubMed/NCBI(In Chinese).

34 

Chen L, Heikkinen L, Wang C, Yang Y, Sun H and Wong G: Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 20:1836–1852. 2019.PubMed/NCBI View Article : Google Scholar

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Ren J, Xu G, Sun H, Lin T, Xu S and Zhao Y: Inhibition of miR‑483‑5p improves the proliferation, invasion and inflammatory response of triple‑negative breast cancer cells by targeting SOCS3. Exp Ther Med 22: 1047, 2021.
APA
Ren, J., Xu, G., Sun, H., Lin, T., Xu, S., & Zhao, Y. (2021). Inhibition of miR‑483‑5p improves the proliferation, invasion and inflammatory response of triple‑negative breast cancer cells by targeting SOCS3. Experimental and Therapeutic Medicine, 22, 1047. https://doi.org/10.3892/etm.2021.10480
MLA
Ren, J., Xu, G., Sun, H., Lin, T., Xu, S., Zhao, Y."Inhibition of miR‑483‑5p improves the proliferation, invasion and inflammatory response of triple‑negative breast cancer cells by targeting SOCS3". Experimental and Therapeutic Medicine 22.4 (2021): 1047.
Chicago
Ren, J., Xu, G., Sun, H., Lin, T., Xu, S., Zhao, Y."Inhibition of miR‑483‑5p improves the proliferation, invasion and inflammatory response of triple‑negative breast cancer cells by targeting SOCS3". Experimental and Therapeutic Medicine 22, no. 4 (2021): 1047. https://doi.org/10.3892/etm.2021.10480
Copy and paste a formatted citation
x
Spandidos Publications style
Ren J, Xu G, Sun H, Lin T, Xu S and Zhao Y: Inhibition of miR‑483‑5p improves the proliferation, invasion and inflammatory response of triple‑negative breast cancer cells by targeting SOCS3. Exp Ther Med 22: 1047, 2021.
APA
Ren, J., Xu, G., Sun, H., Lin, T., Xu, S., & Zhao, Y. (2021). Inhibition of miR‑483‑5p improves the proliferation, invasion and inflammatory response of triple‑negative breast cancer cells by targeting SOCS3. Experimental and Therapeutic Medicine, 22, 1047. https://doi.org/10.3892/etm.2021.10480
MLA
Ren, J., Xu, G., Sun, H., Lin, T., Xu, S., Zhao, Y."Inhibition of miR‑483‑5p improves the proliferation, invasion and inflammatory response of triple‑negative breast cancer cells by targeting SOCS3". Experimental and Therapeutic Medicine 22.4 (2021): 1047.
Chicago
Ren, J., Xu, G., Sun, H., Lin, T., Xu, S., Zhao, Y."Inhibition of miR‑483‑5p improves the proliferation, invasion and inflammatory response of triple‑negative breast cancer cells by targeting SOCS3". Experimental and Therapeutic Medicine 22, no. 4 (2021): 1047. https://doi.org/10.3892/etm.2021.10480
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team